Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
BeyondSpring Inc is a biotechnology business based in the US. BeyondSpring shares (BYSI) are listed on the NASDAQ and all prices are listed in US Dollars. BeyondSpring employs 91 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $3.28 |
|---|---|
| 52-week range | $3.64 - $33.00 |
| 50-day moving average | $7.93 |
| 200-day moving average | $12.85 |
| Wall St. target price | $25.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.91 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.28 from 2022-01-21
| 1 week (2022-01-14) | -15.46% |
|---|---|
| 1 month (2021-12-18) | N/A |
| 3 months (2021-10-22) | -79.49% |
| 6 months (2021-07-22) | -67.10% |
| 1 year (2021-01-22) | -74.09% |
|---|---|
| 2 years (2020-01-22) | -80.67% |
| 3 years (2019-01-22) | 17.6 |
| 5 years (2017-01-18) | N/A |
| Revenue TTM | $1.2 million |
|---|---|
| Gross profit TTM | $180,000 |
| Return on assets TTM | -67.47% |
| Return on equity TTM | -244.37% |
| Profit margin | 0% |
| Book value | $0.98 |
| Market capitalisation | $144.8 million |
TTM: trailing 12 months
We're not expecting BeyondSpring to pay a dividend over the next 12 months.
Over the last 12 months, BeyondSpring's shares have ranged in value from as little as $3.64 up to $33. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BeyondSpring's is 0.8476. This would suggest that BeyondSpring's shares are less volatile than average (for this exchange).
BeyondSpring Inc. , a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and developing Plinabulin, which is in Phase III clinical trial for the treatment of later-stage non-small cell lung cancer (NSCLC). It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.